# Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

> **NCT01374217** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 14 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT01374217
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** early stopping rule
- **Last updated:** 2018-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374217, "Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01374217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*